---
title: "TD Cowen downgrades BioLife Solutions (BLFS) to a Hold"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293527734.md"
description: "TD Cowen analyst Brendan Smith downgraded BioLife Solutions (BLFS) to a Hold with a $31 price target. This follows a similar downgrade by Craig-Hallum, which also set a Hold rating and $31 target for the healthcare stock."
datetime: "2026-07-22T22:05:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293527734.md)
  - [en](https://longbridge.com/en/news/293527734.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293527734.md)
---

# TD Cowen downgrades BioLife Solutions (BLFS) to a Hold

TD Cowen analyst Brendan Smith downgraded BioLife Solutions to a Hold today and set a price target of $31.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Smith covers the Healthcare sector, focusing on stocks such as Twist Bioscience, Evotec AG, and BioLife Solutions. According to TipRanks, Smith has an average return of 16.2% and a 52.85% success rate on recommended stocks.

In a report released today, Craig-Hallum also downgraded the stock to a Hold with a $31.00 price target.

### Related Stocks

- [BLFS.US](https://longbridge.com/en/quote/BLFS.US.md)
- [TWST.US](https://longbridge.com/en/quote/TWST.US.md)
- [EVT.DE](https://longbridge.com/en/quote/EVT.DE.md)
- [EVO.US](https://longbridge.com/en/quote/EVO.US.md)

## Related News & Research

- [BioLife Solutions, Inc. (NASDAQ:BLFS) Receives Consensus Recommendation of "Hold" from Analysts](https://longbridge.com/en/news/293498720.md)
- [Repligen to buy BioLife Solutions for about USD 1.5 billion, offers USD 31 a share](https://longbridge.com/en/news/293454273.md)
- [Are NG, BLFS, NRIM Obtaining Fair Deals for their Shareholders?](https://longbridge.com/en/news/294083853.md)
- [11:34 ETShareholder Alert: Ademi LLP investigates whether BioLife Solutions, Inc. is obtaining a Fair Price for Public Shareholders](https://longbridge.com/en/news/293494670.md)
- [Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?](https://longbridge.com/en/news/293625486.md)